{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-301868","form_type":"8-K","ticker":null,"cik":"0001580063","company_name":"BIORA THERAPEUTICS, INC.","filed_at":"2022-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.261578+00:00","generated_at":"2026-06-21T06:48:30.416474+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biora receives Nasdaq delisting notice for minimum bid price non-compliance","bullets":["Nasdaq Staff notified Biora on Dec 6, 2022 that it fails to meet the minimum bid price requirement under Listing Rule 5450(a)(1).","Company will request a hearing before the Nasdaq Hearings Panel, which will stay any further delisting action pending a decision.","Biora filed a proxy statement on Nov 29 for a Dec 19 special meeting to authorize a reverse stock split (ratio 5:1 to 25:1) as part of a compliance plan.","There is no immediate impact on trading of common stock (symbol BIOR) while the hearing process is ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-301868","json":"https://secwatch.observer/filing/0001193125-22-301868.json","markdown":"https://secwatch.observer/filing/0001193125-22-301868.md","text":"https://secwatch.observer/filing/0001193125-22-301868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/0001193125-22-301868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/d434300d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:48:30.416474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81901b4333c3f90b372c26da84ed97fd6eec369b","claim":"BIORA THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"December 6, 2022, Biora Therapeutics, Inc. (the “ Company ”) received a determination from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, due to the Company’s continued non-compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “ Rule ”), the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company plans to timely request a hearing before the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1580063/000119312522301868/0001193125-22-301868-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}